Ipsen Completes Kartos Acquisition to Expand Oncology Pipeline
Paris, France | August 21, 2026 Ipsen announced the completion of its acquisition of Kartos Therapeutics, strengthening its late-stage...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Paris, France | August 21, 2026 Ipsen announced the completion of its acquisition of Kartos Therapeutics, strengthening its late-stage...
LEXINGTON, Mass., June 26, 2026 Curis, Inc. announced continued progress in its Phase 2 TakeAim CLL clinical trial, confirming...
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
IRVINE, California, May 29, 2026 PeproMene Bio, Inc. has announced that updated clinical data from its ongoing Phase 1...
PRINCETON, N.J. and TOKYO, May 13, 2026 Taiho Oncology and Taiho Pharmaceutical announced that the U.S. Food and Drug...
SAN CARLOS, Calif., May 13, 2026 BeOne Medicines announced that the U.S. Food and Drug Administration (FDA) has granted...
BOSTON, USA, April 22, 2026 PureTech Health plc has announced positive topline results from its Phase 1b clinical trial...
Newton, Massachusetts, USA, April 21, 2026 In a major development in hematologic oncology, Karyopharm Therapeutics Inc. has announced that...
Indianapolis, Indiana | April 13, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3...
TAMPA, FLORIDA, UNITED STATES — February 17, 2026 TuHURA Biosciences has filed an Investigational New Drug (IND) application with...
